Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
Ilyang Pharma exports US$200m ulcer treatment tech to Russia
By 황유미Published : Sept. 5, 2016 - 14:23
[THE INVESTOR] Ilyang Pharmaceutical has signed an agreement to export its technology for its new ulcer treatment Noltec to Russia’s largest pharmaceutical company R-Pharm, the company announced on Sept. 5.
The South Korean pharmaceutical company developed ilaprazole -- trade name Noltec -- in 2008 and the drug’s turnover in the first half of this year reached 6 billion won (US$5.42 million), a 7.2 percent rise from the same period last year.
The US$200 million contract includes exclusive supply of ingredients and finished products in Russia, Armenia and Belarus, and does not include 10 percent royalty based on the sales. The contract will automatically renew every year until the South Korean company’s patent expires.
R-Pharm is a leading pharmaceutical company with annual sales of 1.8 trillion won, and has an exclusive sales right for Ilyang’s leukemia treatment Supect since 2014.
By Hwang You-mee (glamazon@heraldcorp.com)
The South Korean pharmaceutical company developed ilaprazole -- trade name Noltec -- in 2008 and the drug’s turnover in the first half of this year reached 6 billion won (US$5.42 million), a 7.2 percent rise from the same period last year.
The US$200 million contract includes exclusive supply of ingredients and finished products in Russia, Armenia and Belarus, and does not include 10 percent royalty based on the sales. The contract will automatically renew every year until the South Korean company’s patent expires.
R-Pharm is a leading pharmaceutical company with annual sales of 1.8 trillion won, and has an exclusive sales right for Ilyang’s leukemia treatment Supect since 2014.
By Hwang You-mee (glamazon@heraldcorp.com)
